Company profile
Ticker
OCEA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
854177213
OCEA stock data
Latest filings (excl ownership)
RW
Registration withdrawal request
16 Feb 23
S-1/A
IPO registration (amended)
8 Apr 22
S-1/A
IPO registration (amended)
14 Feb 22
S-1/A
IPO registration (amended)
4 Feb 22
S-1/A
IPO registration (amended)
26 Jul 21
CERT
Certification of approval for exchange listing
22 Jul 21
8-A12B
Registration of securities on exchange
20 Jul 21
S-1/A
IPO registration (amended)
20 Jul 21
S-1/A
IPO registration (amended)
14 Jul 21
S-1/A
IPO registration (amended)
22 Jun 21
Latest ownership filings
Institutional ownership, Q2 2024
92.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 44 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.10 bn |
Total shares | 32.06 mm |
Total puts | 103.90 k |
Total calls | 483.01 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Poseidon Bio | 22.84 mm | $0.00 |
Polar Asset Management Partners | 2.69 mm | $3.22 bn |
Aesther Healthcare Sponsor | 1.55 mm | $12.39 mm |
Vellar Opportunities Fund Master | 1.52 mm | $0.00 |
Vanguard | 406.53 k | $495.97 mm |
Fund Management B.V. Privium | 402.25 k | $19.27 mm |
Wolverine Asset Management | 305.60 k | $12.25 mm |
Walleye Capital | 228.02 k | $9.14 mm |
Boothbay Fund Management | 209.60 k | $255.72 mm |
MMCAP International Inc. SPC | 200.00 k | $8.02 mm |
News
Molecure Has Signed An Exclusive Licensing Agreement With Ocean Biomedical For Selective YKL-40 Inhibitor Program, Including The Lead Molecule Oat-3912 For Approximately $32M
15 Oct 24
Ocean Biomedical Announces Publication Of New Data Deepening Understanding Of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 And Its Ability To Inhibit Anti-Tumor And Related Tissue Remodeling Responses
1 Oct 24
Press releases
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
15 Oct 24
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
1 Oct 24
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
27 Aug 24
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
23 Aug 24